<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39314607</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>25</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2168-8184</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><Issue>8</Issue><PubDate><Year>2024</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Cureus</Title><ISOAbbreviation>Cureus</ISOAbbreviation></Journal><ArticleTitle>Enhanced Treatment in Severe-Critical COVID-19 With Tocilizumab, Remdesivir, Dexamethasone: A Jordanian Cohort Study.</ArticleTitle><Pagination><StartPage>e67467</StartPage><MedlinePgn>e67467</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e67467</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.7759/cureus.67467</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Several medications have been proposed to manage COVID-19, with controversial data regarding their clinical benefits. We aimed to investigate the clinical efficacy of using remdesivir (RDV) with and without tocilizumab (TCZ) and standard therapy in treating severe COVID-19.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This retrospective cohort study was conducted in a Jordanian tertiary hospital (September 26th, 2020 - August 28th, 2021) and included adult COVID-19 patients requiring oxygen support. Patients were categorized into three groups based on treatment: TCZ+RDV and standard therapy; RDV and standard therapy; and standard therapy alone, which included dexamethasone, vitamins, anticoagulants, and ceftriaxone.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of 1,556 screened, 1,244 patients (mean age 62.33, 60.8% men) were included. Distribution was 106 in TCZ+RDV, 520 in RDV, and 618 in standard therapy. No significant differences were observed in age, gender, or BMI. Mortality was lowest in TCZ+RDV (32.1%), followed by RDV (40.6%) and standard therapy (47.1%) (p=0.005). Among ICU patients, TCZ+RDV showed significantly lower mortality (51.1%) compared to RDV (75%) and standard therapy (85.8%) (p&lt;0.001). The ICU stays and invasive mandatory ventilation (IMV) durations were significantly shorter with TCZ+RDV (4.30 and 2.69 days, respectively) compared to RDV (7.61 and 4.52 days) and standard therapy (7.98 and 5.32 days) (p&lt;0.001 for ICU stays, p=0.025 for IMV durations).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Combining TCZ, RDV, and dexamethasone shows promise in reducing mortality and ICU/IMV duration for severe COVID-19.</AbstractText><CopyrightInformation>Copyright © 2024, Al-Mistarehi et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Al-Mistarehi</LastName><ForeName>Abdel-Hameed W</ForeName><Initials>AW</Initials><AffiliationInfo><Affiliation>School of Medicine, Johns Hopkins University School of Medicine, Baltimore, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>El-Akawi</LastName><ForeName>Shadi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Internal Medicine, MedStar Washington Hospital Center-Georgetown University, Washington, DC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kheirallah</LastName><ForeName>Khalid A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Jordan University of Science and Technology, Irbid, JOR.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bani Ata</LastName><ForeName>Ehab M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Jordan University of Science and Technology, Irbid, JOR.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zaitoun</LastName><ForeName>Khaled J</ForeName><Initials>KJ</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Jordan University of Science and Technology, Amman, JOR.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khassawneh</LastName><ForeName>Ahmad B</ForeName><Initials>AB</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Jordan University of Science and Technology, Irbid, JOR.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jarrah</LastName><ForeName>Abdullah</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Internal Medicine, Detroit Medical Center/Sinai Grace Hospital/Wayne State University, Detroit, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alzoubi</LastName><ForeName>Hamed M</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Jordan University of Science and Technology, Irbid, JOR.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Azzam</LastName><ForeName>Sayer</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Faculty of Pharmacy, Jordan University of Science and Technology, Irbid, JOR.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karasneh</LastName><ForeName>Reema A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Yarmouk University, Irbid, JOR.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Altawalbeh</LastName><ForeName>Rana B</ForeName><Initials>RB</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Jordan University of Science and Technology, Irbid, JOR.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khassawneh</LastName><ForeName>Basheer</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Jordan University of Science and Technology, Irbid, JOR.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cureus</MedlineTA><NlmUniqueID>101596737</NlmUniqueID><ISSNLinking>2168-8184</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">covid-19 therapy</Keyword><Keyword MajorTopicYN="N">dexamethasone</Keyword><Keyword MajorTopicYN="N">remdesivir</Keyword><Keyword MajorTopicYN="N">tocilizumab</Keyword><Keyword MajorTopicYN="N">treatment outcomes</Keyword></KeywordList><CoiStatement>Human subjects: Consent was obtained or waived by all participants in this study. The Institutional Review Board (IRB) at Jordan University of Science and Technology (JUST) issued approval 27/137/2021. This study was conducted following the 1975 Helsinki Declaration, as revised in 2008, and later amendments or comparable ethical standards. The patients’ information was kept confidential, and the data analysis was conducted on the de-identified database. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>24</Day><Hour>10</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>24</Day><Hour>10</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>24</Day><Hour>4</Hour><Minute>40</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39314607</ArticleId><ArticleId IdType="pmc">PMC11417280</ArticleId><ArticleId IdType="doi">10.7759/cureus.67467</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>A novel coronavirus from patients with pneumonia in China, 2019. Zhu N, Zhang D, Wang W, et al. N Engl J Med. 2020;382:727–733.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7092803</ArticleId><ArticleId IdType="pubmed">31978945</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO declares COVID-19 a pandemic. Cucinotta D, Vanelli M. Acta Biomed. 2020;91:157–160.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7569573</ArticleId><ArticleId IdType="pubmed">32191675</ArticleId></ArticleIdList></Reference><Reference><Citation>An interactive web-based dashboard to track COVID-19 in real time. Dong E, Du H, Gardner L. Lancet Infect Dis. 2020;20:533–534.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7159018</ArticleId><ArticleId IdType="pubmed">32087114</ArticleId></ArticleIdList></Reference><Reference><Citation>Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. Wu Z, McGoogan JM. JAMA. 2020;323:1239–1242.</Citation><ArticleIdList><ArticleId IdType="pubmed">32091533</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID-19 outbreak in Jordan: epidemiological features, clinical characteristics, and laboratory findings. Samrah SM, Al-Mistarehi AW, Ibnian AM, et al.  https://doi.org/10.1016/j.amsu.2020.07.020. Ann Med Surg (Lond) 2020;57:103–108.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7367794</ArticleId><ArticleId IdType="pubmed">32742648</ArticleId></ArticleIdList></Reference><Reference><Citation>A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis. 2020;20:0–7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7292605</ArticleId><ArticleId IdType="pubmed">32539990</ArticleId></ArticleIdList></Reference><Reference><Citation>Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Zhou F, Yu T, Du R, et al. Lancet. 2020;395:1054–1062.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7270627</ArticleId><ArticleId IdType="pubmed">32171076</ArticleId></ArticleIdList></Reference><Reference><Citation>Geneva: World Health Organization; 2020. Clinical Management of Severe Acute Respiratory Infection (SARI) When COVID-19 Disease Is Suspected: Interim Guidance, 13 March.</Citation></Reference><Reference><Citation>Beyond knowledge: evaluating the practices and precautionary measures towards COVID-19 amongst medical doctors in Jordan. Ramadan M, Hasan Z, Saleh T, et al. Int J Clin Pract. 2021;75:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7995122</ArticleId><ArticleId IdType="pubmed">33650228</ArticleId></ArticleIdList></Reference><Reference><Citation>The role of non-state actors in combating COVID-19 spread in Northern Jordan. Khassawneh AH, Alrabadi N, Al-Mistarehi AH, Obeidat N, Kheirallah KA. Ann Med Surg (Lond) 2020;60:484–486.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7649625</ArticleId><ArticleId IdType="pubmed">33194175</ArticleId></ArticleIdList></Reference><Reference><Citation>Jordan’s Pandemic Influenza Preparedness (PIP): a reflection on COVID-19 response. Kheirallah KA, Al-Nusair M, Aljabeiti S, et al. Int J Environ Res Public Health. 2022;19</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9222974</ArticleId><ArticleId IdType="pubmed">35742449</ArticleId></ArticleIdList></Reference><Reference><Citation>Depression and coping among COVID-19-infected individuals after 10 days of mandatory in-hospital quarantine, Irbid, Jordan. Samrah SM, Al-Mistarehi AH, Aleshawi AJ, et al. Psychol Res Behav Manag. 2020;13:823–830.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7547909</ArticleId><ArticleId IdType="pubmed">33116970</ArticleId></ArticleIdList></Reference><Reference><Citation>Self-reported obsession toward COVID-19 preventive measures among undergraduate medical students during the early phase of pandemic in Jordan. Al-Shatanawi TN, Sakka SA, Kheirallah KA, et al. Front Public Health. 2021;9:719668.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8606560</ArticleId><ArticleId IdType="pubmed">34820347</ArticleId></ArticleIdList></Reference><Reference><Citation>Determinants of the willingness of the general population to get vaccinated against COVID-19 in a developing country. Al-Mistarehi AH, Kheirallah KA, Yassin A, et al. Clin Exp Vaccine Res. 2021;10:171–182.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8217585</ArticleId><ArticleId IdType="pubmed">34222130</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug treatments for covid-19: living systematic review and network meta-analysis. Siemieniuk RA, Bartoszko JJ, Zeraatkar D, et al. BMJ. 2020;370:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7390912</ArticleId><ArticleId IdType="pubmed">32732190</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. JAMA. 2020;323:1824–1836.</Citation><ArticleIdList><ArticleId IdType="pubmed">32282022</ArticleId></ArticleIdList></Reference><Reference><Citation>Possible treatment and strategies for COVID-19: review and assessment. Trivedi N, Verma A, Kumar D. Eur Rev Med Pharmacol Sci. 2020;24:12593–12608.</Citation><ArticleIdList><ArticleId IdType="pubmed">33336780</ArticleId></ArticleIdList></Reference><Reference><Citation>A living WHO guideline on drugs for covid-19. Agarwal A, Hunt B, Stegemann M, et al. BMJ. 2020;370:0.</Citation><ArticleIdList><ArticleId IdType="pubmed">32887691</ArticleId></ArticleIdList></Reference><Reference><Citation>Bethesda: National Institutes of Health; 2022. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines.</Citation><ArticleIdList><ArticleId IdType="pubmed">34003615</ArticleId></ArticleIdList></Reference><Reference><Citation>FDA has authorized these therapies to manage patients with COVID-19. Tanzi MG. Pharm Today. 2021;27:18–20.</Citation></Reference><Reference><Citation>Immune therapy, or antiviral therapy, or both for COVID-19: a systematic review. Cantini F, Goletti D, Petrone L, Najafi Fard S, Niccoli L, Foti R. Drugs. 2020;80:1929–1946.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7568461</ArticleId><ArticleId IdType="pubmed">33068263</ArticleId></ArticleIdList></Reference><Reference><Citation>FDA Approves First Treatment for COVID-19. 2020. https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-covid-19 https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-covid-19</Citation></Reference><Reference><Citation>Baricitinib is first approved COVID-19 immunomodulatory treatment. Rubin R. JAMA. 2022;327:2281.</Citation><ArticleIdList><ArticleId IdType="pubmed">35727290</ArticleId></ArticleIdList></Reference><Reference><Citation>Coronavirus (COVID-19) Update: FDA Authorizes Drug for Treatment of COVID-19. 2021. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-drug-treatment-covid-19 https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-drug-treatment-covid-19</Citation></Reference><Reference><Citation>Bethesda: National Institutes of Health; 2022. Anti-SARS-CoV-2 Monoclonal Antibodies | COVID-19 Treatment Guidelines.</Citation></Reference><Reference><Citation>COVID-19: consider cytokine storm syndromes and immunosuppression. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. Lancet. 2020;395:1033–1034.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7270045</ArticleId><ArticleId IdType="pubmed">32192578</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunopathological characteristics of coronavirus disease 2019 cases in Guangzhou, China. Tan M, Liu Y, Zhou R, Deng X, Li F, Liang K, Shi Y. Immunology. 2020;160:261–268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7283723</ArticleId><ArticleId IdType="pubmed">32460357</ArticleId></ArticleIdList></Reference><Reference><Citation>Molecular immune pathogenesis and diagnosis of COVID-19. Li X, Geng M, Peng Y, Meng L, Lu S. J Pharm Anal. 2020;10:102–108.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7104082</ArticleId><ArticleId IdType="pubmed">32282863</ArticleId></ArticleIdList></Reference><Reference><Citation>Viral coagulopathy in patients with COVID-19: treatment and care. Kipshidze N, Dangas G, White CJ, et al. Clin Appl Thromb Hemost. 2020;26:1076029620936776.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7461127</ArticleId><ArticleId IdType="pubmed">32687449</ArticleId></ArticleIdList></Reference><Reference><Citation>Viral clearance course of COVID-19 outbreaks. Samrah SM, Al-Mistarehi AH, Kewan T, Al-Khatib SM, Ibnian AM, Samrah RS, Khassawneh BY. J Multidiscip Healthc. 2021;14:555–565.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7941054</ArticleId><ArticleId IdType="pubmed">33707949</ArticleId></ArticleIdList></Reference><Reference><Citation>Mortality rate and biomarker expression within COVID-19 patients who develop acute ischemic stroke: a systematic review and meta-analysis. Yassin A, Ghzawi A, Al-Mistarehi AH, et al. Future Sci OA. 2021;7:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8114837</ArticleId><ArticleId IdType="pubmed">34254031</ArticleId></ArticleIdList></Reference><Reference><Citation>Neutrophil extracellular traps in COVID-19. Zuo Y, Yalavarthi S, Shi H, et al. JCI Insight. 2020;5</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7308057</ArticleId><ArticleId IdType="pubmed">32329756</ArticleId></ArticleIdList></Reference><Reference><Citation>Antiinflammatory action of glucocorticoids--new mechanisms for old drugs. Rhen T, Cidlowski JA. N Engl J Med. 2005;353:1711–1723.</Citation><ArticleIdList><ArticleId IdType="pubmed">16236742</ArticleId></ArticleIdList></Reference><Reference><Citation>Dexamethasone in hospitalized patients with COVID-19. Horby P, Lim WS, Emberson JR, et al. N Engl J Med. 2021;384:693–704.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7383595</ArticleId><ArticleId IdType="pubmed">32678530</ArticleId></ArticleIdList></Reference><Reference><Citation>Dexamethasone in hospitalised COVID-19 patients not on intensive respiratory support. Crothers K, DeFaccio R, Tate J, et al. Eur Respir J. 2022;60</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8841623</ArticleId><ArticleId IdType="pubmed">34824060</ArticleId></ArticleIdList></Reference><Reference><Citation>Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial. Tomazini BM, Maia IS, Cavalcanti AB, et al. JAMA. 2020;324:1307–1316.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7489411</ArticleId><ArticleId IdType="pubmed">32876695</ArticleId></ArticleIdList></Reference><Reference><Citation>Tocilizumab and remdesivir in hospitalized patients with severe COVID-19 pneumonia: a randomized clinical trial. Rosas IO, Diaz G, Gottlieb RL, et al. Intensive Care Med. 2021;47:1258–1270.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8490137</ArticleId><ArticleId IdType="pubmed">34609549</ArticleId></ArticleIdList></Reference><Reference><Citation>Impact of adding remdesivir to tocilizumab in hospitalized patients with coronavirus disease. Schneider CA, Martinez J, Jodoin K, Wolowich WR. Int J Infect Dis Epidemiol. 2021;7:238.</Citation></Reference><Reference><Citation>The use of single therapy with tocilizumab versus combination therapy with remdesivir and tocilizumab in SARS-CoV-2 patients in El Paso, Texas. Almaghlouth NK, Anyiam FE, Shah S, Haq S, Attia MJ, Guevara R, Antony S. Cureus. 2021;13:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8276197</ArticleId><ArticleId IdType="pubmed">34277310</ArticleId></ArticleIdList></Reference><Reference><Citation>Efficacy of the early treatment with tocilizumab-hydroxychloroquine and tocilizumab-remdesivir in severe COVID-19 patients. Sarhan RM, Harb HS, Abou Warda AE, et al. J Infect Public Health. 2022;15:116–122.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8562044</ArticleId><ArticleId IdType="pubmed">34764044</ArticleId></ArticleIdList></Reference><Reference><Citation>Success rate of remdesivir, convalescent plasma, and tocilizumab in moderate to severe COVID-19 pneumonia: our experience in a tertiary care center. Mohanty B, Sunder A, Satyanarayan B, Kumar M, Shukla R, Ahmed A. J Family Med Prim Care. 2021;10:4236–4241.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8797123</ArticleId><ArticleId IdType="pubmed">35136795</ArticleId></ArticleIdList></Reference><Reference><Citation>Combination therapy with remdesivir, dexamethasone, and tocilizumab in patients with severe corona virus disease [Preprint] Izumo T, Inomata M, Kuse N, et al. Res Square. 2020</Citation></Reference><Reference><Citation>Efficacy and outcome of remdesivir and tocilizumab combination against dexamethasone for the treatment of severe COVID-19: a randomized controlled trial. Mohiuddin Chowdhury AT, Kamal A, Abbas KU, et al. Front Pharmacol. 2022;13:690726.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9017992</ArticleId><ArticleId IdType="pubmed">35450050</ArticleId></ArticleIdList></Reference><Reference><Citation>Notes from the field: the combined effects of tocilizumab and remdesivir in a patient with severe COVID-19 and cytokine release syndrome. Ali S, Khalid S, Afridi M, Akhtar S, Khader YS, Akhtar H. JMIR Public Health Surveill. 2021;7:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8136404</ArticleId><ArticleId IdType="pubmed">34009133</ArticleId></ArticleIdList></Reference><Reference><Citation>Use of tocilizumab, remdesivir, and high-dose methylprednisolone prevents intubation in an ESRD patient with COVID-19 pneumonia. Judge R, Kolaski S, Qadeer F. SAGE Open Med Case Rep. 2022;10:2050313.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8755926</ArticleId><ArticleId IdType="pubmed">35035974</ArticleId></ArticleIdList></Reference><Reference><Citation>Tocilizumab and remdesivir in a pregnant patient with coronavirus disease 2019 (COVID-19) Naqvi M, Zakowski P, Glucksman L, Smithson S, Burwick RM. Obstet Gynecol. 2020;136:1025–1029.</Citation><ArticleIdList><ArticleId IdType="pubmed">32618794</ArticleId></ArticleIdList></Reference><Reference><Citation>Report of a combination of remdesivir, intravenous methylprednisolone pulse, and tocilizumab for severe coronavirus disease: 20-case series at a single institution. Ichiyama T, Komatsu M, Wada Y, Hanaoka M. https://doi.org/10.1016/j.resinv.2022.04.001 Respir Investig. 2022;60:604–606.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9035365</ArticleId><ArticleId IdType="pubmed">35501265</ArticleId></ArticleIdList></Reference><Reference><Citation>Improved survival among hospitalized patients with coronavirus disease 2019 (COVID-19) treated with remdesivir and dexamethasone. A nationwide population-based cohort study. Benfield T, Bodilsen J, Brieghel C, et al. Clin Infect Dis. 2021;73:2031–2036.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8344480</ArticleId><ArticleId IdType="pubmed">34111274</ArticleId></ArticleIdList></Reference><Reference><Citation>Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis. Shankar-Hari M, Vale CL, Godolphin PJ, et al. JAMA. 2021;326:499–518.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8261689</ArticleId><ArticleId IdType="pubmed">34228774</ArticleId></ArticleIdList></Reference><Reference><Citation>Prevalence estimates and risk factors of anxiety among healthcare workers in Jordan over one year of the COVID-19 pandemic: a cross-sectional study. Yassin A, Al-Mistarehi AH, El-Salem K, et al. Int J Environ Res Public Health. 2022;19</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8909996</ArticleId><ArticleId IdType="pubmed">35270333</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends of prevalence estimates and risk factors of depressive symptoms among healthcare workers over one year of the COVID-19 pandemic. Yassin A, Al-Mistarehi AH, Soudah O, et al. Clin Pract Epidemiol Ment Health. 2022;18:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10158079</ArticleId><ArticleId IdType="pubmed">37274865</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends in insomnia, burnout, and functional impairment among health care providers over the first year of the COVID-19 pandemic. Yassin A, Al-Mistarehi AH, Qarqash AA, et al. Clin Pract Epidemiol Ment Health. 2022;18:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10156054</ArticleId><ArticleId IdType="pubmed">37274859</ArticleId></ArticleIdList></Reference><Reference><Citation>Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: a randomized clinical trial. Salvarani C, Dolci G, Massari M, et al. JAMA Intern Med. 2021;181:24–31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7577199</ArticleId><ArticleId IdType="pubmed">33080005</ArticleId></ArticleIdList></Reference><Reference><Citation>Tocilizumab for treatment of patients with severe COVID-19: a retrospective cohort study. Kewan T, Covut F, Al-Jaghbeer MJ, Rose L, Gopalakrishna KV, Akbik B. EClinicalMedicine. 2020;24:100418.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7305505</ArticleId><ArticleId IdType="pubmed">32766537</ArticleId></ArticleIdList></Reference><Reference><Citation>Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Wang Y, Zhang D, Du G, et al. Lancet. 2020;395:1569–1578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7190303</ArticleId><ArticleId IdType="pubmed">32423584</ArticleId></ArticleIdList></Reference><Reference><Citation>UpToDate. Waltham: UpToDate; 2024. Lexicomp: Tocilizumab: Drug information.</Citation></Reference><Reference><Citation>Remdesivir use in the setting of severe renal impairment: a theoretical concern or real risk? Pettit NN, Pisano J, Nguyen CT, Lew AK, Hazra A, Sherer R, Mullane KM. Clin Infect Dis. 2021;73:0–5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7799321</ArticleId><ArticleId IdType="pubmed">33315065</ArticleId></ArticleIdList></Reference><Reference><Citation>Executive summary of the clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. Arch Intern Med. 1998;158:1855–1867.</Citation><ArticleIdList><ArticleId IdType="pubmed">9759681</ArticleId></ArticleIdList></Reference><Reference><Citation>Charlson Comorbidity Index: ICD-9 update and ICD-10 translation. Glasheen WP, Cordier T, Gumpina R, Haugh G, Davis J, Renda A. https://pubmed.ncbi.nlm.nih.gov/31428236/ Am Health Drug Benefits. 2019;12:188–197.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6684052</ArticleId><ArticleId IdType="pubmed">31428236</ArticleId></ArticleIdList></Reference><Reference><Citation>Clinical Spectrum | COVID-19 Treatment Guidelines. 2021. https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/ https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/</Citation></Reference><Reference><Citation>Effectiveness of non-invasive ventilation in intensive care unit admitted patients due to SARS-CoV-2 pneumonia. Belenguer Muncharaz A, Hernández-Garcés H, López-Chicote C, Ribes-García S, Ochagavía-Barbarín J, Zaragoza-Crespo R. Med Intensiva (Engl Ed) 2021;45:0–8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8547964</ArticleId><ArticleId IdType="pubmed">34776402</ArticleId></ArticleIdList></Reference><Reference><Citation>Effectiveness of remdesivir in patients with COVID-19 under mechanical ventilation in an Italian ICU. Pasquini Z, Montalti R, Temperoni C, et al. J Antimicrob Chemother. 2020;75:3359–3365.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7499641</ArticleId><ArticleId IdType="pubmed">32829390</ArticleId></ArticleIdList></Reference><Reference><Citation>Mortality-related risk factors of COVID-19: a systematic review and meta-analysis of 42 studies and 423,117 patients. Dessie ZG, Zewotir T. BMC Infect Dis. 2021;21:855.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8380115</ArticleId><ArticleId IdType="pubmed">34418980</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID-19 mortality risk for older men and women. Yanez ND, Weiss NS, Romand JA, Treggiari MM. BMC Public Health. 2020;20:1742.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7675386</ArticleId><ArticleId IdType="pubmed">33213391</ArticleId></ArticleIdList></Reference><Reference><Citation>Diabetes, hypertension, body mass index, smoking and COVID-19-related mortality: a systematic review and meta-analysis of observational studies. Mahamat-Saleh Y, Fiolet T, Rebeaud ME, et al. BMJ Open. 2021;11:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8557249</ArticleId><ArticleId IdType="pubmed">34697120</ArticleId></ArticleIdList></Reference><Reference><Citation>Impact of chronic kidney disease on severity and mortality in COVID-19 patients: a systematic review and meta-analysis. Menon T, Gandhi SA, Tariq W, et al. Cureus. 2021;13:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8093366</ArticleId><ArticleId IdType="pubmed">33959457</ArticleId></ArticleIdList></Reference><Reference><Citation>Predictors of invasive mechanical ventilation in hospitalized COVID-19 patients: a retrospective study from Jordan. Kabbaha S, Al-Azzam S, Karasneh RA, et al. Expert Rev Respir Med. 2022;16:945–952.</Citation><ArticleIdList><ArticleId IdType="pubmed">35929952</ArticleId></ArticleIdList></Reference><Reference><Citation>Antibiotics in treatment of COVID-19 complications: a review of frequency, indications, and efficacy. Chedid M, Waked R, Haddad E, Chetata N, Saliba G, Choucair J. https://doi.org/10.1016/j.jiph.2021.02.001. J Infect Public Health. 2021;14:570–576.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7870433</ArticleId><ArticleId IdType="pubmed">33848886</ArticleId></ArticleIdList></Reference><Reference><Citation>Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. Chen T, Wu D, Chen H, et al. BMJ. 2020;368:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7190011</ArticleId><ArticleId IdType="pubmed">32217556</ArticleId></ArticleIdList></Reference><Reference><Citation>Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Yang X, Yu Y, Xu J, et al. Lancet Respir Med. 2020;8:475–481.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7102538</ArticleId><ArticleId IdType="pubmed">32105632</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>